Inactive Instrument

Highlights Bavarian Nordic A/S CBOE EUROPE EQUITIES

Equities

DK0015998017

Real-time Estimate Cboe Europe Other stock markets 10:55:00 2024-06-06 EDT
181 ^DKK	0.00%

05-31	Bavarian Nordic Files for Supplemental US License for Smallpox-Monkeypox Vaccine	MT
05-30	Bavarian Nordic Gets $6.5 Million Funding for Development of Mpox Vaccine in Children	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Bavarian Nordic Files for Supplemental US License for Smallpox-Monkeypox Vaccine	05-31	MT
Bavarian Nordic Gets $6.5 Million Funding for Development of Mpox Vaccine in Children	05-30	MT
Bavarian Nordic A/S and Coalition for Epidemic Preparedness Innovations Partners to Advance Mpox Vaccination in Africa	05-30	CI
Bavarian Nordic A/S commences an Equity Buyback Plan, under the authorization approved on April 16, 2024.	05-08	CI
Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024	05-08	CI
Bavarian Nordic A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Bavarian Nordic Books EUR65 Million Order for Smallpox Vaccine	04-30	MT
Bavarian Nordic A/S Receives EUR 65 Million Contract to Supply Smallpox Vaccines for EU Strategic Reserve	04-29	CI
Bavarian Nordic Starts US Rolling Submission Process for Chikungunya Vaccine Candidate	04-29	MT
Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate	04-29	CI
Bavarian Nordic A/S's Equity Buyback announced on May 9, 2023, has expired.	04-15	CI
Swiss Regulator Clears Bavarian Nordic’s Jynneos for Smallpox Immunization in Adults	03-13	MT
Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland	03-13	CI
Bavarian Nordic A/S Reports Earnings Results for the Full Year Ended December 31, 2023	03-06	CI
Bavarian Nordic A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-05	CI
Bavarian Nordic A/S Announces Accelerated Assessment for the Upcoming Marketing Authorisation Application for CHIKV VLP	02-23	CI
Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024	02-21	CI
Bavarian Nordic Confirms FY23 Revenue Growth Outlook	11-16	MT
Bavarian Nordic A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-16	CI
Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023	11-16	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Bavarian Nordic A/S CBOE EUROPE EQUITIES

Equities

DK0015998017

Highlights

Filters